Acadia Pharmaceuticals (ACAD) Intangibles (2016 - 2026)

Acadia Pharmaceuticals' Intangibles history runs 10 years deep, the most recent figure standing at $106.2 million for Q1 2026.

• On a quarterly basis, Intangibles fell 9.3% year-over-year to $106.2 million in Q1 2026; TTM through Mar 2026 was $106.2 million, a 9.3% decrease from a year earlier, with the FY2025 full-year figure at $108.9 million, down 9.09% from the prior year.
• Intangibles slipped to $106.2 million in Q1 2026 per ACAD's latest filing, from $108.9 million in the prior quarter.
• Across five years, Intangibles topped out at $119.8 million in Q4 2024 and bottomed at $65.5 million in Q4 2023.
• The 4-year median for Intangibles is $107.9 million (2024), against an average of $98.5 million.
• Across the five-year window, Intangibles jumped 82.9% in 2024 and declined 9.3% in 2026, its largest moves.
• Year by year, Intangibles stood at $65.5 million in 2023, then jumped by 82.9% to $119.8 million in 2024, then fell by 9.09% to $108.9 million in 2025, then retreated by 2.5% to $106.2 million in 2026.
• Per Business Quant, the three latest ACAD Intangibles figures stand at $106.2 million (Q1 2026), $108.9 million (Q4 2025), and $111.6 million (Q3 2025).